再鼎醫藥(09688.HK):一季度產品收入6280萬美元 同比增長36%
格隆匯5月10日丨再鼎醫藥(09688.HK)發佈公吿,2023年第一季度產品收入合計為6280萬美元,同比增長36%;則樂銷售收入同比增長44%。就新一代腫瘤抗體偶聯藥物(ADC)項目達成戰略合作,進一步拓展了再鼎醫藥的肺癌管線和全球腫瘤管線。穩健的資產負債狀況,截至2023年3月31日現金儲備為9.314億美元,截至2022年12月31日為10.093億美元。
再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“儘管年初遭遇疫情放開後的挑戰,我們第一季度的公司業績和進展仍舊展現了再鼎醫藥潛在的全球同類最佳產品組合和強大的執行力。KarXT用於精神分裂症的3期研究EMERGENT-3的陽性關鍵性結果和 TIVDAK用於治療頭頸部癌的2期研究innovaTV 207的陽性中期分析,使我們更加堅信這些藥物將是中國乃至全球患者的重要治療選擇。我們也非常高興美國食品藥品監督管理局(FDA)諮詢委員會一致支持批准舒巴坦鈉-度洛巴坦鈉,這將是第一款精準靶向針對由不動桿菌引起的嚴重乃至危及生命的感染的療法。”
“近期我們通過新一代DLL3 ADC項目ZL-1310的合作,進一步拓展了公司的肺癌管線,豐富了我們的全球腫瘤管線。此次全球ADC項目的合作,表明我們將持續關注ADC領域。這款產品是對我們的肺癌領域管線的有力補充,我們將利用再鼎醫藥的強大能力推進開發ZL-1310,並期待相關臨牀結果。”
“我期待帶領再鼎醫藥進入下一個轉型新階段,不斷增長、提升生產力並抓住全球機遇。為了更好地支持我的工作,幫助滿足我們的業務在下一增長階段的戰略和運營需求,我們高興地宣佈已晉升Josh Smiley為總裁兼首席運營官。Josh的豐富經驗和戰略眼光將幫助我們進一步成長為全球領先的生物製藥公司,實現我們改善人類健康的使命,以及在中國及更多地區推動創新的企業戰略目標。”杜瑩博士總結道。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.